Genzyme Corporation-Product Pipeline Review-2015

Genzyme Corporation-Product Pipeline Review-2015

  • Products Id :- GMDHC06784CDB
  • |
  • Pages: 74
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Genzyme Corporation-Product Pipeline Review-2015


Global Markets Direct's, 'Genzyme Corporation-Product Pipeline Review-2015', provides an overview of the Genzyme Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Genzyme Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Genzyme Corporation including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Genzyme Corporation's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Genzyme Corporation's pipeline products

Reasons To Buy

Evaluate Genzyme Corporation's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Genzyme Corporation in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Genzyme Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Genzyme Corporation and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Genzyme Corporation

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Genzyme Corporation and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Genzyme Corporation Snapshot 6

Genzyme Corporation Overview 6

Key Information 6

Key Facts 6

Genzyme Corporation-Research and Development Overview 7

Key Therapeutic Areas 7

Genzyme Corporation-Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products-Monotherapy 11

Pipeline Products-Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Genzyme Corporation-Pipeline Products Glance 14

Genzyme Corporation-Late Stage Pipeline Products 14

Pre-Registration Products/Combination Treatment Modalities 14

Phase III Products/Combination Treatment Modalities 15

Genzyme Corporation-Clinical Stage Pipeline Products 16

Phase II Products/Combination Treatment Modalities 16

Phase I Products/Combination Treatment Modalities 17

Genzyme Corporation-Early Stage Pipeline Products 18

Preclinical Products/Combination Treatment Modalities 18

Discovery Products/Combination Treatment Modalities 19

Genzyme Corporation-Drug Profiles 20

eliglustat tartrate 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

patisiran 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

revusiran 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

sargramostim 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

GZ-402666 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

fresolimumab 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Genz-682452 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

GZ-402671 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Olipodase 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

GZ-402663 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

GZ-402668 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

1D-11 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Antisense Oligonucleotide for Spinal Muscular Atrophy and Myotonic Dystrophy 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

GENZ-644442 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

GENZ-668764 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Small Molecules for Malaria 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Small Molecules to Inhibit PMP22 for Charcot-Marie-Tooth Type 1 A 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Genzyme Corporation-Pipeline Analysis 42

Genzyme Corporation-Pipeline Products by Target 42

Genzyme Corporation-Pipeline Products by Route of Administration 44

Genzyme Corporation-Pipeline Products by Molecule Type 45

Genzyme Corporation-Pipeline Products by Mechanism of Action 46

Genzyme Corporation-Recent Pipeline Updates 47

Genzyme Corporation-Dormant Projects 58

Genzyme Corporation-Discontinued Pipeline Products 60

Discontinued Pipeline Product Profiles 60

ataluren 60

Genz-644470 60

GZ-402674 60

GZ-404477 60

metelimumab 61

tasidotin hydrochloride 61

teriflunomide 61

tolevamer potassium sodium 61

Genzyme Corporation-Locations And Subsidiaries 62

Head Office 62

Other Locations & Subsidiaries 62

Genzyme Corporation-Key Manufacturing Facilities 72

Appendix 73

Methodology 73

Coverage 73

Secondary Research 73

Primary Research 73

Expert Panel Validation 73

Contact Us 73

Disclaimer 74

List of Tables

Genzyme Corporation, Key Information 6

Genzyme Corporation, Key Facts 6

Genzyme Corporation-Pipeline by Indication, 2015 9

Genzyme Corporation-Pipeline by Stage of Development, 2015 10

Genzyme Corporation-Monotherapy Products in Pipeline, 2015 11

Genzyme Corporation-Partnered Products in Pipeline, 2015 12

Genzyme Corporation-Partnered Products/ Combination Treatment Modalities, 2015 13

Genzyme Corporation-Pre-Registration, 2015 14

Genzyme Corporation-Phase III, 2015 15

Genzyme Corporation-Phase II, 2015 16

Genzyme Corporation-Phase I, 2015 17

Genzyme Corporation-Preclinical, 2015 18

Genzyme Corporation-Discovery, 2015 19

Genzyme Corporation-Pipeline by Target, 2015 43

Genzyme Corporation-Pipeline by Route of Administration, 2015 44

Genzyme Corporation-Pipeline by Molecule Type, 2015 45

Genzyme Corporation-Pipeline Products by Mechanism of Action, 2015 46

Genzyme Corporation-Recent Pipeline Updates, 2015 47

Genzyme Corporation-Dormant Developmental Projects,2015 58

Genzyme Corporation-Discontinued Pipeline Products, 2015 60

Genzyme Corporation, Other Locations 62

Genzyme Corporation, Subsidiaries 68

Genzyme Corporation, Key Manufacturing Facilities 72

List of Figures

Genzyme Corporation-Pipeline by Top 10 Indication, 2015 8

Genzyme Corporation-Pipeline by Stage of Development, 2015 10

Genzyme Corporation-Monotherapy Products in Pipeline, 2015 11

Genzyme Corporation-Partnered Products in Pipeline, 2015 12

Genzyme Corporation-Pipeline by Top 10 Target, 2015 42

Genzyme Corporation-Pipeline by Top 10 Route of Administration, 2015 44

Genzyme Corporation-Pipeline by Top 10 Molecule Type, 2015 45

Genzyme Corporation-Pipeline Products by Top 10 Mechanism of Action, 2015 46

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Genzyme Corporation; Genzyme Corporation - Key Therapeutics; Genzyme Corporation - Pipeline Overview and Promising Molecules; Genzyme Corporation - News; Genzyme Corporation - Latest Updates; Genzyme Corporation - Pipeline; Genzyme Corporation - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 102135
Site License
USD 3000 INR 204270
Corporate User License
USD 4500 INR 306405



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]